Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 38%
Buy 57%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health demonstrates strong growth prospects, with a year-over-year revenue increase of 7% despite challenging comparisons, underscoring its innovation in data offerings and strategic partnerships with electronic medical records. The company maintains a leading position in the circulating genomic profiling liquid biopsy market, holding over 50% market share, and has achieved nearly 30% year-over-year growth since its inception in 2014. Additionally, recent advancements in reimbursement coverage for its Reveal and Shield tests suggest a promising trajectory for average selling price expansion and volume growth, further enhancing the company's financial outlook.

Bears say

The analysis of Guardant Health's financial outlook reveals significant concerns regarding reimbursement dynamics that may negatively impact average selling prices (ASP) and overall profitability. Notably, the potential implementation of PAMA regulations could result in a one-time revenue decline of approximately $100 million, further complicating the financial landscape for the company. Additionally, uncertainties in the regulatory environment for multi-cancer early detection (MCED) tests pose risks to adoption rates, potentially hindering the company's growth trajectory and financial performance.

GH has been analyzed by 21 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 57% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 21 analysts, GH has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.